{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"160"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"}],"units":"Participants"}],"description":"Treatment-emergent AEs were defined as those events that occurred on or after the first dose of study drug, through the treatment phase, and within 30 days following the last dose of study drug.","groups":[{"description":"All participants in this study received both study drugs and were therefore analysed together as a single treatment arm.\n\nParticipants receiving the different regimens were not analysed separately by regimen, as the study was designed to assess the safety of the combination study treatment.\n\nThe study included N=161 participants who received both acalabrutinib and pembrolizumab and are summarized together (from First stage safety lead-in and Second stage expansion). Stage 3 (additional expansion in subjects with Myelofibrosis) was planned but not conducted.","id":"OG000","title":"Acalabrutinib + Pembrolizumab"}],"paramType":"NUMBER","populationDescription":"All participants in this study received both study drugs and were therefore analyzed together as a single treatment arm. Participants receiving the different regimens were not analyzed separately by regimen, as the study was designed to assess the safety of the combination study treatment.","reportingStatus":"POSTED","timeFrame":"104 weeks","title":"Number of Participants With Treatment Emergent Adverse Events (AEs)","type":"PRIMARY","unitOfMeasure":"Number of participants"}